NCT01212666

Brief Summary

The Purpose of this study is to determine whether Adductor-Canal-Block is superior to placebo when it comes to analgetic efficacy after reconstruction of the anterior cruciate ligament.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started May 2010

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2010

Completed
25 days until next milestone

First Submitted

Initial submission to the registry

May 26, 2010

Completed
4 months until next milestone

First Posted

Study publicly available on registry

October 1, 2010

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2012

Completed
Last Updated

September 11, 2012

Status Verified

September 1, 2012

Enrollment Period

1.8 years

First QC Date

May 26, 2010

Last Update Submit

September 9, 2012

Conditions

Keywords

Adductor Canal Block (ACB)Anterior Cruciate Ligament (ACL) ReconstructionSaphenous nervePainUltrasound block

Outcome Measures

Primary Outcomes (1)

  • Pain-score (VAS), patient standing

    Pain-score messured on a Visual Analog Scale (VAS) 2 hours after adductor canal block. Patient standing. Intervention-group vs. placebo-group.

    2 hours postoperative

Secondary Outcomes (38)

  • Total Opioid-consumption

    0-24 hours postoperative

  • Postoperative Nausea and Vomiting

    0 hour postoperative

  • Postoperative ondansetron consumption

    In hospital

  • Pain-score (VAS), patient at rest

    0 hours postoperative

  • Pain-score (VAS), patient at rest

    1 hour postoperative

  • +33 more secondary outcomes

Study Arms (2)

Adductor-Canal-Block, Ropivacain

EXPERIMENTAL

25 patients. ACB. 30 mL Ropivacain 7,5 mg/mL. Ultrasound-guided application.

Procedure: Ropivacain

Adductor Canal Block, Placebo (saline)

PLACEBO COMPARATOR

25 patients. ACB. 30 mL Saline. Ultrasound-guided application.

Procedure: Saline

Interventions

RopivacainPROCEDURE

Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.

Also known as: Naropin
Adductor-Canal-Block, Ropivacain
SalinePROCEDURE

Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.

Adductor Canal Block, Placebo (saline)

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • years
  • Reconstruction of Anterior Cruciate Ligament
  • Written consent
  • ASA I-II
  • BMI 19-35

You may not qualify if:

  • Unable to communicate in Danish
  • Allergic reactions toward drugs used in the trial
  • Pregnancy
  • Abuse of alcohol/drugs
  • Daily opioid intake
  • Infection at injection site
  • Can not be mobilised to 5 meters of walk; pre-surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Anaesthesiology, Glostrup University Hospital

Copenhagen, Glostrup, 2600, Denmark

Location

Related Publications (1)

  • Espelund M, Fomsgaard JS, Haraszuk J, Mathiesen O, Dahl JB. Analgesic efficacy of ultrasound-guided adductor canal blockade after arthroscopic anterior cruciate ligament reconstruction: a randomised controlled trial. Eur J Anaesthesiol. 2013 Jul;30(7):422-8. doi: 10.1097/EJA.0b013e328360bdb9.

MeSH Terms

Conditions

Pain

Interventions

RopivacaineSodium Chloride

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Malene Espelund, MD

    Glostrup University Hospital, Copenhagen

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

May 26, 2010

First Posted

October 1, 2010

Study Start

May 1, 2010

Primary Completion

March 1, 2012

Study Completion

March 1, 2012

Last Updated

September 11, 2012

Record last verified: 2012-09

Locations